TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more
TME Pharma N.V. (ALTME) - Total Liabilities
Latest total liabilities as of June 2025: €2.86 Million EUR
Based on the latest financial reports, TME Pharma N.V. (ALTME) has total liabilities worth €2.86 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TME Pharma N.V. - Total Liabilities Trend (2014–2024)
This chart illustrates how TME Pharma N.V.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TME Pharma N.V. Competitors by Total Liabilities
The table below lists competitors of TME Pharma N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hoyne Bancorp, Inc. Common Stock
NASDAQ:HYNE
|
USA | $364.61 Million |
|
IHI Corp
BE:IWJ
|
Germany | €1.77 Trillion |
|
CF Acquisition Corp. VII Warrant
NASDAQ:CFFSW
|
USA | $12.74 Million |
|
Kuchai Develop Bhd
KLSE:2186
|
Malaysia | RM1.73 Million |
|
GUESS? (GU9.SG)
STU:GU9
|
Germany | €2.24 Billion |
|
Can Fite Biopharma Ltd
TA:CANF
|
Israel | ILA3.54 Million |
|
AOZORA BANK
MU:AON
|
Germany | €7.21 Trillion |
Liability Composition Analysis (2014–2024)
This chart breaks down TME Pharma N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TME Pharma N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TME Pharma N.V. (2014–2024)
The table below shows the annual total liabilities of TME Pharma N.V. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.79 Million | -35.66% |
| 2023-12-31 | €2.79 Million | -57.24% |
| 2022-12-31 | €6.51 Million | +23.68% |
| 2021-12-31 | €5.27 Million | +78.15% |
| 2020-12-31 | €2.96 Million | -17.57% |
| 2019-12-31 | €3.59 Million | -49.67% |
| 2018-12-31 | €7.12 Million | +46.97% |
| 2017-12-31 | €4.85 Million | -9.40% |
| 2016-12-31 | €5.35 Million | -59.07% |
| 2015-12-31 | €13.07 Million | +40.07% |
| 2014-12-31 | €9.33 Million | -- |